UK’s MHRA Accepts Biosplice’s Application for Lorecivivint (LOR) in Knee Osteoarthritis and Begins Assessment

RegulatoryLORPositive

AI Analysis

Summary

The UK MHRA has accepted Biosplice's application for lorecivivint (LOR) in knee osteoarthritis and commenced assessment, with a planned submission to the European Medicines Agency expected later in the month.

Outcome Details

UK MHRA accepted application and began assessment

Importance:5/10

Sentiment:

0.60

regulatoryUKMHRAosteoarthritislorecivivint

Related Companies

$UTHR

Read the original article

Published by GlobeNewswire Clinical Studies on September 8, 2026 10:30 AM

Read Original